Patients With Cancer Clinical Trial
Official title:
Ivabradine to Prevent Anthracycline-induced Cardiotoxicity: a Prospective Randomized Open Label Clinical Trial
The aim of this study is to investigate protective effects of ivabradine in adult cancer patients undergoing anthracycline-based chemotherapy.
Cancer treatment with anthracyclines may cause heart damage and can lead to heart failure.
There are drugs which may protect against cardiotoxic effects of anthracyclines
(renin-angiotensin inhibitors and beta blockers), but they are not tolerated due to
hypotension. Ivabradine is heart rate lowering drug without effect on blood pressure which
was approved for treatment of angina pectoris and heart failure. The aim of this study is to
investigate protective effects of ivabradine in cancer patients undergoing
anthracycline-based chemotherapy.
Ivabradine selectively inhibits If currents in the sinus node and prolongs the duration of
spontaneous depolarization. That controls the heart's contractions and regulates the heart
rate. Additionally, ivabradine might preserve myocardial function and contractility without
effect on blood pressure. Ivabradine was approved for symptomatic treatment of chronic stable
angina pectoris and chronic heart failure.
The aim of this study is to investigate protective effects of ivabradine in adult cancer
patients undergoing anthracycline-based chemotherapy.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT01242943 -
Radioimmunotherapy With 131I-L19SIP in Patients With Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06041607 -
Shared Meditation Involving People With Cancer, Carers and Third Parties
|
N/A | |
| Completed |
NCT05520372 -
Autologous Immune Enhancement Therapy (AIET) for Cancer Patients
|
Phase 1 | |
| Recruiting |
NCT05273541 -
Safety and Immunogenicity of Prime-boost Vaccination of SARS-CoV-2 in Patients With Cancer
|
Phase 1/Phase 2 |